(NASDAQ: SRDX) Surmodics's forecast annual revenue growth rate of 9.94% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.02%.
Surmodics's revenue in 2025 is $125,448,000.On average, 2 Wall Street analysts forecast SRDX's revenue for 2025 to be $1,935,606,649, with the lowest SRDX revenue forecast at $1,934,105,569, and the highest SRDX revenue forecast at $1,937,107,729. On average, 2 Wall Street analysts forecast SRDX's revenue for 2026 to be $2,147,544,820, with the lowest SRDX revenue forecast at $2,133,391,782, and the highest SRDX revenue forecast at $2,161,697,858.
In 2027, SRDX is forecast to generate $2,429,318,940 in revenue, with the lowest revenue forecast at $2,429,318,940 and the highest revenue forecast at $2,429,318,940.